Share Price and Basic Stock Data
Last Updated: February 13, 2026, 10:20 pm
| PEG Ratio | 0.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fermenta Biotech Ltd operates in the pharmaceuticals sector and reported a market capitalization of ₹916 Cr with a share price of ₹311. The company’s sales figures revealed fluctuations over recent quarters, with the highest quarterly sales of ₹156 Cr recorded in December 2024, while the lowest was ₹55 Cr in December 2022. For the trailing twelve months (TTM), total sales stood at ₹563 Cr. Annual sales have shown a mixed trajectory, with ₹468 Cr reported for FY 2025, a notable recovery from ₹349 Cr in FY 2023. This indicates a growth trend, particularly compared to the previous year, despite the dip in FY 2024 with sales at ₹335 Cr. The company’s ability to generate consistent revenue is critical in a highly competitive landscape, reflecting its strategic positioning and operational capabilities.
Profitability and Efficiency Metrics
Profitability metrics for Fermenta Biotech Ltd showcase a volatile performance, with the operating profit margin (OPM) fluctuating significantly. The OPM stood at 25.90% for FY 2025, a stark recovery from just 5% in FY 2023, indicating effective cost management and improved operational efficiency. Net profits also reflected this trend, with ₹76 Cr in FY 2025, reversing a loss of ₹53 Cr in FY 2023. The return on equity (ROE) was strong at 24.9%, while the return on capital employed (ROCE) was at 23.0%, both suggesting efficient use of capital. However, the cash conversion cycle (CCC) was reported at 189 days, indicating potential inefficiencies in working capital management, which could pose a risk if not addressed.
Balance Sheet Strength and Financial Ratios
Fermenta Biotech’s balance sheet displays a robust structure with total reserves of ₹376 Cr and borrowings of ₹112 Cr, resulting in a low debt-to-equity ratio of 0.30. This indicates a conservative leverage position, enhancing financial stability. The interest coverage ratio (ICR) was strong at 8.57x, suggesting the company generates sufficient earnings to cover its interest obligations comfortably. Additionally, the company reported a price-to-book value (P/BV) of 2.20x, which is in line with sector norms, indicating that the market values the company positively relative to its net assets. The current ratio at 1.58x reflects adequate liquidity to meet short-term obligations. However, the declining trend in fixed assets, which stood at ₹227 Cr in FY 2025, raises questions about future capital investments and asset utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fermenta Biotech Ltd demonstrates a strong promoter holding of 64.08%, indicating significant insider confidence in the company’s prospects. Institutional ownership is minimal, with foreign institutional investors (FIIs) holding just 0.02% as of March 2025, suggesting limited institutional interest compared to other companies in the sector. The public shareholding stood at 34.75% with a total of 13,760 shareholders, reflecting a diverse investor base. The gradual reduction in the number of shareholders from 17,610 in December 2022 to the current figure may suggest consolidation but also raises concerns about retail investor sentiment. The lack of significant institutional backing could limit the stock’s potential for upward momentum, particularly in turbulent market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Fermenta Biotech Ltd faces both opportunities and challenges. The recovery in sales and profitability is promising, but the company must address its cash conversion cycle to enhance liquidity. Risks include potential volatility in raw material costs and regulatory challenges inherent in the pharmaceutical sector, which could impact margins. Additionally, the low institutional investor interest might hinder stock performance during market downturns. However, if the company continues to improve operational efficiencies and leverage its strong balance sheet, it could capitalize on growth opportunities in the pharmaceuticals market. Overall, while the outlook appears optimistic, careful monitoring of operational performance and market dynamics will be essential for sustained growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 137/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,402 Cr. | 312 | 479/192 | 71.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 338 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,956.81 Cr | 1,098.00 | 54.79 | 201.74 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98 | 55 | 105 | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 | 130 |
| Expenses | 95 | 65 | 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 |
| Operating Profit | 3 | -10 | 19 | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 | 27 |
| OPM % | 3% | -18% | 18% | 13% | -24% | 25% | 6% | 1% | 20% | 34% | 26% | 21% | 20% |
| Other Income | 3 | -19 | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 |
| Interest | 5 | 5 | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 |
| Depreciation | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 |
| Profit before tax | -8 | -41 | -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 | 24 |
| Tax % | 6% | -8% | 373% | -0% | -0% | 38% | 885% | -0% | 6% | 16% | -4% | 23% | 25% |
| Net Profit | -8 | -38 | -5 | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 | 18 |
| EPS in Rs | -2.75 | -12.70 | -1.40 | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.42 |
Last Updated: February 2, 2026, 12:46 am
Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 130.00 Cr.. The value appears to be declining and may need further review. It has decreased from 136.00 Cr. (Jun 2025) to 130.00 Cr., marking a decrease of 6.00 Cr..
- For Expenses, as of Sep 2025, the value is 104.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 108.00 Cr. (Jun 2025) to 104.00 Cr., marking a decrease of 4.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 27.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Jun 2025) to 20.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 24.00 Cr., marking a decrease of 4.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Jun 2025) to 25.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Jun 2025) to 18.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 6.42. The value appears to be declining and may need further review. It has decreased from 7.42 (Jun 2025) to 6.42, marking a decrease of 1.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 563 |
| Expenses | 113 | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 418 |
| Operating Profit | 26 | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 145 |
| OPM % | 19% | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 26% |
| Other Income | 3 | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 20 |
| Interest | 5 | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 |
| Depreciation | 10 | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 23 |
| Profit before tax | 14 | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 130 |
| Tax % | 24% | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | |
| Net Profit | 10 | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 111 |
| EPS in Rs | 2.86 | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 38.06 |
| Dividend Payout % | 29% | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -90.00% | 100.00% | -550.00% | 611.11% | 154.35% | -48.72% | -28.33% | -65.12% | -453.33% | 54.72% | 416.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 190.00% | -650.00% | 1161.11% | -456.76% | -203.07% | 20.38% | -36.78% | -388.22% | 508.05% | 361.95% |
Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 7% |
| 3 Years: | 74% |
| TTM: | 532% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -3% |
| 3 Years: | 10% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| Last Year: | 25% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 15 |
| Reserves | 130 | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 376 |
| Borrowings | 65 | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 112 |
| Other Liabilities | 61 | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 149 |
| Total Liabilities | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
| Fixed Assets | 87 | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 219 |
| CWIP | 36 | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 26 |
| Investments | 17 | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 118 | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 406 |
| Total Assets | 259 | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 651 |
Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Reserves, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 348.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 112.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 115.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 149.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 219.00 Cr.. The value appears to be declining and may need further review. It has decreased from 227.00 Cr. (Mar 2025) to 219.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 372.00 Cr. (Mar 2025) to 406.00 Cr., marking an increase of 34.00 Cr..
- For Total Assets, as of Sep 2025, the value is 651.00 Cr.. The value appears strong and on an upward trend. It has increased from 614.00 Cr. (Mar 2025) to 651.00 Cr., marking an increase of 37.00 Cr..
Notably, the Reserves (376.00 Cr.) exceed the Borrowings (112.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -39.00 | -55.00 | -68.00 | -75.00 | -80.00 | -53.00 | -158.00 | -149.00 | -177.00 | -202.00 | -111.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 |
| Inventory Days | 149 | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 306 |
| Days Payable | 120 | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 192 |
| Cash Conversion Cycle | 136 | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 189 |
| Working Capital Days | 9 | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 |
| ROCE % | 9% | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.77 |
| Diluted EPS (Rs.) | 26.35 | -7.99 | -17.85 | 5.33 | 15.69 |
| Cash EPS (Rs.) | 34.50 | 0.24 | -8.77 | 14.08 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 124.33 | 98.76 | 108.08 | 128.76 | 124.90 |
| Revenue From Operations / Share (Rs.) | 160.95 | 116.25 | 121.27 | 138.15 | 130.79 |
| PBDIT / Share (Rs.) | 41.69 | 13.62 | 8.88 | 24.12 | 31.17 |
| PBIT / Share (Rs.) | 33.39 | 5.06 | -0.90 | 15.26 | 24.13 |
| PBT / Share (Rs.) | 28.53 | -3.42 | -17.98 | 9.34 | 17.90 |
| Net Profit / Share (Rs.) | 26.19 | -8.31 | -18.56 | 5.22 | 14.74 |
| NP After MI And SOA / Share (Rs.) | 26.35 | -7.99 | -17.85 | 5.35 | 15.77 |
| PBDIT Margin (%) | 25.90 | 11.71 | 7.32 | 17.46 | 23.83 |
| PBIT Margin (%) | 20.74 | 4.34 | -0.74 | 11.04 | 18.44 |
| PBT Margin (%) | 17.72 | -2.94 | -14.82 | 6.76 | 13.68 |
| Net Profit Margin (%) | 16.27 | -7.15 | -15.30 | 3.77 | 11.27 |
| NP After MI And SOA Margin (%) | 16.37 | -6.86 | -14.71 | 3.87 | 12.06 |
| Return on Networth / Equity (%) | 21.19 | -7.98 | -16.36 | 4.15 | 12.62 |
| Return on Capital Employeed (%) | 24.19 | 3.89 | -0.61 | 8.81 | 14.56 |
| Return On Assets (%) | 12.50 | -4.20 | -8.09 | 2.18 | 6.62 |
| Long Term Debt / Equity (X) | 0.04 | 0.14 | 0.26 | 0.30 | 0.30 |
| Total Debt / Equity (X) | 0.30 | 0.45 | 0.68 | 0.63 | 0.57 |
| Asset Turnover Ratio (%) | 0.80 | 0.56 | 0.52 | 0.55 | 0.57 |
| Current Ratio (X) | 1.58 | 1.40 | 1.21 | 1.52 | 1.48 |
| Quick Ratio (X) | 0.99 | 0.89 | 0.58 | 0.74 | 0.70 |
| Inventory Turnover Ratio (X) | 4.45 | 0.70 | 0.77 | 0.91 | 1.06 |
| Dividend Payout Ratio (NP) (%) | 4.69 | -15.65 | -7.00 | 46.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.57 | 217.49 | -15.50 | 17.58 | 0.00 |
| Earning Retention Ratio (%) | 95.31 | 115.65 | 107.00 | 53.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.43 | -117.49 | 115.50 | 82.42 | 0.00 |
| Interest Coverage Ratio (X) | 8.57 | 2.31 | 1.23 | 4.07 | 5.00 |
| Interest Coverage Ratio (Post Tax) (X) | 6.38 | 0.02 | -0.20 | 1.88 | 3.37 |
| Enterprise Value (Cr.) | 831.46 | 505.89 | 464.45 | 795.24 | 883.96 |
| EV / Net Operating Revenue (X) | 1.77 | 1.51 | 1.33 | 2.00 | 2.34 |
| EV / EBITDA (X) | 6.84 | 12.87 | 18.12 | 11.43 | 9.83 |
| MarketCap / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| Retention Ratios (%) | 95.30 | 115.65 | 107.00 | 53.31 | 0.00 |
| Price / BV (X) | 2.20 | 1.51 | 0.98 | 1.59 | 2.00 |
| Price / Net Operating Revenue (X) | 1.70 | 1.30 | 0.88 | 1.49 | 1.91 |
| EarningsYield | 0.09 | -0.05 | -0.16 | 0.02 | 0.06 |
After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 34.50. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 34.50, marking an increase of 34.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 124.33. It has increased from 98.76 (Mar 24) to 124.33, marking an increase of 25.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 160.95. It has increased from 116.25 (Mar 24) to 160.95, marking an increase of 44.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 41.69. This value is within the healthy range. It has increased from 13.62 (Mar 24) to 41.69, marking an increase of 28.07.
- For PBIT / Share (Rs.), as of Mar 25, the value is 33.39. This value is within the healthy range. It has increased from 5.06 (Mar 24) to 33.39, marking an increase of 28.33.
- For PBT / Share (Rs.), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from -3.42 (Mar 24) to 28.53, marking an increase of 31.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 26.19. This value is within the healthy range. It has increased from -8.31 (Mar 24) to 26.19, marking an increase of 34.50.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 26.35. This value is within the healthy range. It has increased from -7.99 (Mar 24) to 26.35, marking an increase of 34.34.
- For PBDIT Margin (%), as of Mar 25, the value is 25.90. This value is within the healthy range. It has increased from 11.71 (Mar 24) to 25.90, marking an increase of 14.19.
- For PBIT Margin (%), as of Mar 25, the value is 20.74. This value exceeds the healthy maximum of 20. It has increased from 4.34 (Mar 24) to 20.74, marking an increase of 16.40.
- For PBT Margin (%), as of Mar 25, the value is 17.72. This value is within the healthy range. It has increased from -2.94 (Mar 24) to 17.72, marking an increase of 20.66.
- For Net Profit Margin (%), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from -7.15 (Mar 24) to 16.27, marking an increase of 23.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.37. This value is within the healthy range. It has increased from -6.86 (Mar 24) to 16.37, marking an increase of 23.23.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.19. This value is within the healthy range. It has increased from -7.98 (Mar 24) to 21.19, marking an increase of 29.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 24.19. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 24.19, marking an increase of 20.30.
- For Return On Assets (%), as of Mar 25, the value is 12.50. This value is within the healthy range. It has increased from -4.20 (Mar 24) to 12.50, marking an increase of 16.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.14 (Mar 24) to 0.04, marking a decrease of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.45 (Mar 24) to 0.30, marking a decrease of 0.15.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.80. It has increased from 0.56 (Mar 24) to 0.80, marking an increase of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.58. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.58, marking an increase of 0.18.
- For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.99, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.45. This value is within the healthy range. It has increased from 0.70 (Mar 24) to 4.45, marking an increase of 3.75.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 20. It has increased from -15.65 (Mar 24) to 4.69, marking an increase of 20.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 20. It has decreased from 217.49 (Mar 24) to 3.57, marking a decrease of 213.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.31. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.31, marking a decrease of 20.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.43. This value exceeds the healthy maximum of 70. It has increased from -117.49 (Mar 24) to 96.43, marking an increase of 213.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 8.57, marking an increase of 6.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.38. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 6.38, marking an increase of 6.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 831.46. It has increased from 505.89 (Mar 24) to 831.46, marking an increase of 325.57.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.77, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 6.84. This value is within the healthy range. It has decreased from 12.87 (Mar 24) to 6.84, marking a decrease of 6.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 95.30. This value exceeds the healthy maximum of 70. It has decreased from 115.65 (Mar 24) to 95.30, marking a decrease of 20.35.
- For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 2.20, marking an increase of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.70, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.09, marking an increase of 0.14.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
- Net Profit Margin: 16.27%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.19% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.99
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 10.3 (Industry average Stock P/E: 54.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.27%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-1501, Thane One, DIL Complex, Thane Maharashtra 400610 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep M Chandan | Chairman & Ind.Dire (Non-Exe) |
| Mr. Krishna Datla | Exe.Vice Chairman & Whole Time Director |
| Mr. Prashant Nagre | Managing Director |
| Mr. Satish Varma | Executive Director |
| Ms. Anupama Datla Desai | Executive Director |
| Ms. Rajeshwari Datla | Non Executive Director |
| Mr. Pramod Kasat | Ind. Non-Executive Director |
| Ms. Rajashri Ojha | Ind. Non-Executive Director |
| Mr. Ramanand Mundkur | Independent Director |
FAQ
What is the intrinsic value of Fermenta Biotech Ltd?
Fermenta Biotech Ltd's intrinsic value (as of 15 February 2026) is ₹408.79 which is 31.44% higher the current market price of ₹311.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹915 Cr. market cap, FY2025-2026 high/low of ₹399/219, reserves of ₹376 Cr, and liabilities of ₹651 Cr.
What is the Market Cap of Fermenta Biotech Ltd?
The Market Cap of Fermenta Biotech Ltd is 915 Cr..
What is the current Stock Price of Fermenta Biotech Ltd as on 15 February 2026?
The current stock price of Fermenta Biotech Ltd as on 15 February 2026 is ₹311.
What is the High / Low of Fermenta Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fermenta Biotech Ltd stocks is ₹399/219.
What is the Stock P/E of Fermenta Biotech Ltd?
The Stock P/E of Fermenta Biotech Ltd is 10.3.
What is the Book Value of Fermenta Biotech Ltd?
The Book Value of Fermenta Biotech Ltd is 133.
What is the Dividend Yield of Fermenta Biotech Ltd?
The Dividend Yield of Fermenta Biotech Ltd is 0.80 %.
What is the ROCE of Fermenta Biotech Ltd?
The ROCE of Fermenta Biotech Ltd is 23.0 %.
What is the ROE of Fermenta Biotech Ltd?
The ROE of Fermenta Biotech Ltd is 24.9 %.
What is the Face Value of Fermenta Biotech Ltd?
The Face Value of Fermenta Biotech Ltd is 5.00.